

Lothar Seefried

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7733546/publications.pdf>

Version: 2024-02-01

49
papers

1,492
citations

331259

21
h-index

344852

36
g-index

76
all docs

76
docs citations

76
times ranked

1860
citing authors

#	ARTICLE	IF	CITATIONS
1	The Transcriptional Profile of Mesenchymal Stem Cell Populations in Primary Osteoporosis Is Distinct and Shows Overexpression of Osteogenic Inhibitors. <i>PLoS ONE</i> , 2012, 7, e45142.	1.1	158
2	BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1496-1504.	3.1	107
3	Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 4-17.	0.5	84
4	Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 755-759.	1.0	74
5	BMP12 and BMP13 gene transfer induce ligamentogenic differentiation in mesenchymal progenitor and anterior cruciate ligament cells. <i>Cytotherapy</i> , 2010, 12, 505-513.	0.3	70
6	Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 80.	0.8	69
7	Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. <i>Bone</i> , 2009, 44, 858-864.	1.4	64
8	Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. <i>Journal of Clinical Investigation</i> , 2017, 127, 2148-2158.	3.9	64
9	Clinical Aspects of Hypophosphatasia: An Update. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2013, 11, 60-70.	1.3	52
10	Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia "not atypical at all. <i>Osteoporosis International</i> , 2018, 29, 1815-1825.	1.3	44
11	High Prevalence of Vitamin D Deficiency in Patients With Bone Marrow Edema Syndrome of the Foot and Ankle. <i>Foot and Ankle International</i> , 2017, 38, 760-766.	1.1	42
12	Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. <i>Nature Reviews Endocrinology</i> , 2022, 18, 366-384.	4.3	42
13	FGF23 is a putative marker for bone healing and regeneration. <i>Journal of Orthopaedic Research</i> , 2009, 27, 1141-1146.	1.2	41
14	Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. <i>Osteoporosis International</i> , 2021, 32, 7-22.	1.3	41
15	Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2171-2178.	3.1	38
16	Primary Osteoporosis Is Not Reflected by Disease-Specific DNA Methylation or Accelerated Epigenetic Age in Blood. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 356-361.	3.1	33
17	Distribution of Constituents and Metabolites of Maritime Pine Bark Extract (Pycnogenol®) into Serum, Blood Cells, and Synovial Fluid of Patients with Severe Osteoarthritis: A Randomized Controlled Trial. <i>Nutrients</i> , 2017, 9, 443.	1.7	32
18	Bone mineral density and fracture risk in adult patients with hypophosphatasia. <i>Osteoporosis International</i> , 2021, 32, 377-385.	1.3	27

#	ARTICLE	IF	CITATIONS
19	Challenges in the management of tumor-induced osteomalacia (TIO). <i>Bone</i> , 2021, 152, 116064.	1.4	27
20	Physical Function and Health-Related Quality of Life in Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia. <i>JBMR Plus</i> , 2020, 4, e10395.	1.3	26
21	Cellular pharmacodynamic effects of Pycnogenol® in patients with severe osteoarthritis: a randomized controlled pilot study. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 537.	3.7	25
22	Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 212.	1.2	22
23	Asfotase alfa: Enzyme replacement for the treatment of bone disease in hypophosphatasia. <i>Drugs of Today</i> , 2016, 52, 271.	0.7	21
24	A small scale cell culture system to analyze mechanobiology using reporter gene constructs and polyurethane dishes. , 2010, 20, 344-355.		20
25	Epidermal growth factor as a mechanosensitizer in human bone marrow stromal cells. <i>Stem Cell Research</i> , 2017, 24, 69-76.	0.3	18
26	Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. <i>Bone</i> , 2021, 142, 115664.	1.4	15
27	Relevant genetic variants are common in women with pregnancy and lactation-associated osteoporosis (PLO) and predispose to more severe clinical manifestations. <i>Bone</i> , 2021, 147, 115911.	1.4	14
28	Genetic Diagnostics in Routine Osteological Assessment of Adult Low Bone Mass Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3048-e3057.	1.8	12
29	Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. <i>Osteoporosis International</i> , 2021, 32, 2505-2513.	1.3	11
30	Frakturheilung bei Osteoporose. <i>Osteologie</i> , 2007, 16, 71-84.	0.1	10
31	Recombinant Enzyme Replacement Therapy in Hypophosphatasia. <i>Sub-Cellular Biochemistry</i> , 2015, 76, 323-341.	1.0	9
32	Penetration of topical diclofenac into synovial tissue and fluid of osteoarthritic knees: a multicenter, randomized, placebo-controlled, pharmacokinetic study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094308.	1.2	9
33	Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS). <i>Journal of Bone and Mineral Research</i> , 2020, 37, 420-427.	3.1	9
34	Lower limb bone geometry in adult individuals with X-linked hypophosphatemia: an observational study. <i>Osteoporosis International</i> , 2022, 33, 1601-1611.	1.3	8
35	Dissection of mechanoreponse elements in promoter sites of the mechanoresponsive CYR61 gene. <i>Experimental Cell Research</i> , 2017, 354, 103-111.	1.2	7
36	Mineral Intake and Clinical Symptoms in Adult Patients with Hypophosphatasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2982-e2992.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of whole body vibration in maintenance hemodialysis patients - A pilot study. Journal of Musculoskeletal Neuronal Interactions, 2017, 17, 268-274.	0.1	7
38	Aldo Castellani " an Appraisal of his Life and Oeuvre Aldo Castellani " sein Leben und sein Werk. Mycoses, 1989, 32, 391-397.	1.8	5
39	Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance. Journal of Bone Oncology, 2020, 25, 100323.	1.0	5
40	Biology of Mesenchymal Stem Cells. Current Rheumatology Reviews, 2008, 4, 148-154.	0.4	3
41	Physical contact between mesenchymal stem cells and endothelial precursors induces distinct signatures with relevance to the very early phase of regeneration. Journal of Cellular Biochemistry, 2018, 119, 9122-9140.	1.2	3
42	Differential impact of osteoporosis, sarcopenia and obesity on physical performance in aging men. Endocrine Connections, 2021, 10, 256-264.	0.8	3
43	Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric Onset Hypophosphatasia. Journal of Clinical Pharmacology, 2021, 61, 1334-1343.	1.0	3
44	Influence of hormones on osteogenic differentiation processes of mesenchymal stem cells. Expert Review of Endocrinology and Metabolism, 2007, 2, 59-78.	1.2	2
45	Trace Elements and Bone. , 2011, , 81-86.		2
46	Diagnostic Findings and Treatment in a 51-Year-Old Woman With Oncogenic Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 385-386.	1.8	2
47	Genetics and future therapy prospects of fibrodysplasia ossificans progressiva. Medizinische Genetik, 2020, 31, 391-396.	0.1	2
48	Sarcopenia and Malnutrition Screening in Female Osteoporosis Patients " A Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 2344.	1.0	2
49	Feasibility of simple exercise interventions for men with osteoporosis " A prospective randomized controlled pilot study. Bone Reports, 2021, 15, 101099.	0.2	1